AbbVie's Dividend Yield Dips: Still a Top Pick?

AbbVie, a favorite for income investors since its 2013 spin-off from Abbott Labs, has seen its dividend yield decrease to around 2.6%, the lowest level since early 2018. This yield compression is primarily driven by the company's substantial stock price growth of approximately 676% since 2013, significantly outpacing its dividend increases. AbbVie continues its legacy as a Dividend King, marking 54 consecutive years of dividend hikes.

The drugmaker's future looks bright, especially with its blockbuster immunology drugs, Skyrizi and Rinvoq. These successors to Humira are on track for combined sales exceeding $29 billion in 2026, surpassing Humira's peak annual sales of around $22 billion. Both drugs demonstrated strong year-over-year sales growth of over 24% in Q2 2026.

AbbVie's robust pipeline includes about 90 programs in clinical development, bolstered by the recent acquisition of Apogee Therapeutics. While Wall Street analysts project moderate near-term stock appreciation, some, like analysts from Morgan Stanley and Scotiabank, are more optimistic, forecasting gains of 14% and 18%, respectively. The reliable and consistently growing dividend makes AbbVie a compelling choice for income-focused investors, with potential for yield on cost to exceed 4.6% in a decade.